RE:RE:RE:RE:RE:TLT Successfully Completes Non-GLP Toxicity Study for GBMRutherrin® to be IV administered for numerous other cancers; including: Non-Small Cell Lung Cancer ("NSCLC"), pancreatic cancer, prostate cancer, kidney cancer and colorectal cancer.